

Association of Plasma Total Tau Level With Cognitive D Impairment or Dementia in the Mayo Clinic Study on A

JAMA Neurology

74, 1073

DOI: 10.1001/jamaneurol.2017.1359

Citation Report

#	ARTICLE	IF	CITATIONS
1	Neurofilaments in blood. <i>Neurology</i> , 2017, 89, 2126-2127.	1.1	0
2	Plasma phospho- τ 181 increases with Alzheimer's disease clinical severity and is associated with τ - and amyloid- β positron emission tomography. <i>Alzheimer's and Dementia</i> , 2018, 14, 989-997.	0.8	386
3	Elevated tau and interleukin-6 concentrations in adults with obstructive sleep apnea. <i>Sleep Medicine</i> , 2018, 43, 71-76.	1.6	73
4	WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2018, 5, 1-4.	2.7	7
5	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	7.7	370
6	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018, 14, 639-652.	10.1	434
7	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. <i>Annals of Neurology</i> , 2018, 84, 648-658.	5.3	230
8	From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S271-S279.	2.6	66
9	Biomarcadores sanguíneos en la enfermedad de Alzheimer. <i>Neurología</i> , 2021, 36, 704-710.	0.7	11
10	Biomarkers of dementia in obstructive sleep apnea. <i>Sleep Medicine Reviews</i> , 2018, 42, 139-148.	8.5	63
11	Association of telomere length with general cognitive trajectories: a meta-analysis of four prospective cohort studies. <i>Neurobiology of Aging</i> , 2018, 69, 111-116.	3.1	32
12	Plasma tau complements CSF tau and β -tau in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 483-492.	2.4	86
13	Blood amyloid levels and risk of dementia in the Ginkgo Evaluation of Memory Study (GEMS): A longitudinal analysis. <i>Alzheimer's and Dementia</i> , 2019, 15, 1029-1038.	0.8	14
14	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019, 7, 5.	5.2	125
15	Soluble TREM1 concentrations are increased and positively correlated with total tau levels in the plasma of patients with Alzheimer's disease. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1801-1805.	2.9	21
16	PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-5.	2.7	43
17	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2019, 76, 969.	9.0	65
18	Plasma Tau and Amyloid Are Not Reliably Related to Injury Characteristics, Neuropsychological Performance, or White Matter Integrity in Service Members with a History of Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 2190-2199.	3.4	24

#	ARTICLE	IF	CITATIONS
19	Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. JAMA Neurology, 2019, 76, 598.	9.0	143
20	Blood-based molecular biomarkers for Alzheimer's disease. Molecular Brain, 2019, 12, 26.	2.6	180
21	Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology. Neurology and Therapy, 2019, 8, 95-111.	3.2	16
22	In Longitudinal Framingham Study, Total Tau Levels in Blood Rise Years Before a Diagnosis of Dementia. Neurology Today: an Official Publication of the American Academy of Neurology, 2019, 19, 5-6.	0.0	0
23	Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. Frontiers in Cell and Developmental Biology, 2019, 7, 313.	3.7	91
24	Predictive Value of Routine Peripheral Blood Biomarkers in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 332.	3.4	46
25	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881.	3.5	46
26	An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform. Neurology and Therapy, 2019, 8, 73-82.	3.2	83
27	Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 487-496.	0.8	94
28	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
29	Blood-based biomarkers for Alzheimer's disease—An update. Journal of Neuroscience Methods, 2019, 319, 2-6.	2.5	87
30	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	2.2	163
31	Occupational metals exposure and cognitive performance among foundry workers using tau protein as a biomarker. NeuroToxicology, 2020, 76, 10-16.	3.0	18
32	Tau inhibits PKA by nuclear proteasome-dependent PKAR21± elevation with suppressed CREB/GluA1 phosphorylation. Aging Cell, 2020, 19, e13055.	6.7	22
33	From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathologica, 2020, 139, 3-25.	7.7	134
34	Exploring Relationships Among Peripheral Amyloid Beta, Tau, Cytokines, Cognitive Function, and Psychosomatic Symptoms in Breast Cancer Survivors. Biological Research for Nursing, 2020, 22, 126-138.	1.9	20
35	Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnesic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial). Trials, 2020, 21, 19.	1.6	4
36	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41.	1.1	20

#	ARTICLE	IF	CITATIONS
37	An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. <i>Current Opinion in Neurobiology</i> , 2020, 61, 29-39.	4.2	67
38	Advances and considerations in AD tau-targeted immunotherapy. <i>Neurobiology of Disease</i> , 2020, 134, 104707.	4.4	70
39	Elevated Tau in Military Personnel Relates to Chronic Symptoms Following Traumatic Brain Injury. <i>Journal of Head Trauma Rehabilitation</i> , 2020, 35, 66-73.	1.7	29
40	Challenges and Advances in Antemortem Diagnosis of Human Transmissible Spongiform Encephalopathies. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 585896.	4.1	16
41	Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights. <i>Journal of Personalized Medicine</i> , 2020, 10, 61.	2.5	35
42	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. <i>Journal of Personalized Medicine</i> , 2020, 10, 221.	2.5	20
43	Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8673.	4.1	8
44	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147.	6.2	23
45	Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	244
46	Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β -40, Amyloid β -42, Tau Protein, and YKL-40: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 3452.	2.4	19
47	The pathway to secondary prevention of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12069.	3.7	5
48	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. <i>Journal of Personalized Medicine</i> , 2020, 10, 116.	2.5	26
49	Cerebrovascular disease promotes tau pathology in Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa132.	3.3	46
50	Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study. <i>Annals of Neurology</i> , 2020, 88, 1065-1076.	5.3	81
51	Tau-induced upregulation of C/EBP β -TRPC1-SCN5A signaling aggravates tauopathies: A vicious cycle in Alzheimer neurodegeneration. <i>Aging Cell</i> , 2020, 19, e13209.	6.7	12
52	Plasma τ NT1 is a Specific and Early Marker of Alzheimer's Disease. <i>Annals of Neurology</i> , 2020, 88, 878-892.	5.3	24
53	Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia. <i>Seminars in Neurology</i> , 2020, 40, 394-410.	1.4	7
54	Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer's Disease. <i>Brain Sciences</i> , 2020, 10, 815.	2.3	6

#	ARTICLE	IF	CITATIONS
55	Blood biomarkers in Alzheimer's disease. <i>Neurologia (English Edition)</i> , 2021, 36, 704-710.	0.4	16
56	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 60-70.	3.1	35
57	β -amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline. <i>Communications Biology</i> , 2020, 3, 352.	4.4	63
58	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , 2020, 26, 387-397.	30.7	471
59	Serum tau levels are increased in patients with hyperthyroidism. <i>Neuroscience Letters</i> , 2020, 729, 135003.	2.1	5
60	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	10.1	121
61	Dysregulation of Exosome Cargo by Mutant Tau Expressed in Human-induced Pluripotent Stem Cell (iPSC) Neurons Revealed by Proteomics Analyses. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 1017-1034.	3.8	34
62	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021, 185, 108081.	4.1	27
63	A preliminary study about neurofilament light chain and tau protein levels in psoriasis: Correlation with disease severity. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23564.	2.1	4
64	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	7.6	124
65	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021, 18, 27-48.	3.0	8
66	Impact of Tau on Neurovascular Pathology in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 573324.	2.4	24
67	Astrocytic expression of the Alzheimer's disease risk allele, ApoE ϵ 4, potentiates neuronal tau pathology in multiple preclinical models. <i>Scientific Reports</i> , 2021, 11, 3438.	3.3	19
68	Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer's disease: a systematic review and meta-analysis. <i>Translational Neurodegeneration</i> , 2021, 10, 10.	8.0	21
69	Peripheral Markers of Neurovascular Unit Integrity and Amyloid- β in the Brains of Menopausal Women. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 397-405.	2.6	4
70	Recent advances in pre-clinical diagnosis of Alzheimer's disease. <i>Metabolic Brain Disease</i> , 2021, , 1.	2.9	3
71	Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 86.	6.2	19
72	Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage. <i>Current Neuropharmacology</i> , 2022, 20, 713-737.	2.9	8

#	ARTICLE	IF	CITATIONS
73	Metabolomics: A Scoping Review of Its Role as a Tool for Disease Biomarker Discovery in Selected Non-Communicable Diseases. <i>Metabolites</i> , 2021, 11, 418.	2.9	45
74	Repurposing bromocriptine for A β 2 metabolism in Alzheimer's disease (REBRAND) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. <i>BMJ Open</i> , 2021, 11, e051343.	1.9	9
75	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	6.0	54
76	Cognitive Impairment and Dementia After Stroke: Design and Rationale for the DISCOVERY Study. <i>Stroke</i> , 2021, 52, e499-e516.	2.0	43
77	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 949-967.	2.8	4
78	Longitudinal Association of Total Tau Concentrations and Physical Activity With Cognitive Decline in a Population Sample. <i>JAMA Network Open</i> , 2021, 4, e2120398.	5.9	19
79	Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. <i>Journal of Neurochemistry</i> , 2021, 159, 211-233.	3.9	29
80	SIRT1 Regulates Tau Expression and Tau Synaptic Pathology. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 895-904.	2.6	7
81	Assessment of High Risk for Alzheimer's Disease Using Plasma Biomarkers in Subjects with Normal Cognition in Taiwan: A Preliminary Study. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 761-770.	2.2	4
82	Epigenetic treatment of behavioral and physiological deficits in a tauopathy mouse model. <i>Aging Cell</i> , 2021, 20, e13456.	6.7	15
83	Blood biomarkers for the diagnosis of amnesic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 479-486.	6.1	35
84	Predictive Accuracy of Blood-Derived Biomarkers for Amyloid- β 2 Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1-15.	2.6	6
85	Diagnostic accuracy of blood biomarkers for Alzheimer's disease and amnesic mild cognitive impairment: A meta-analysis. <i>Ageing Research Reviews</i> , 2021, 71, 101446.	10.9	15
86	Sex differences in CSF biomarkers of Alzheimer's disease. , 2021, , 107-123.		0
88	Plasma tau predicts cerebral vulnerability in aging. <i>Aging</i> , 2020, 12, 21004-21022.	3.1	5
89	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 177-191.	3.7	17
90	Performance of Plasma Amyloid β 2, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 749649.	3.4	9
91	Emerging blood-based biomarkers for Alzheimer disease. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 537-539.	1.3	1

#	ARTICLE	IF	CITATIONS
92	Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. <i>Metabolic Brain Disease</i> , 2022, 37, 67-104.	2.9	24
93	Plasma Total Tau and Neurobehavioral Symptoms of Cognitive Decline in Cognitively Normal Older Adults. <i>Frontiers in Psychology</i> , 2021, 12, 774049.	2.1	4
94	Changes in Organ Systems over the Lifespan. , 2021, , 7-25.		0
96	Protopine promotes the proteasomal degradation of pathological tau in Alzheimer's disease models via HDAC6 inhibition. <i>Phytomedicine</i> , 2022, 96, 153887.	5.3	30
97	Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention. <i>Ageing Research Reviews</i> , 2022, 74, 101544.	10.9	60
98	Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 9.	6.2	2
99	Prospects for the use of graphene-based biological sensors in the early diagnosis of Alzheimer's disease (review of literature). <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2022, 67, 5-12.	0.5	0
100	Tau proteins in blood as biomarkers of Alzheimer's disease and other proteinopathies. <i>Journal of Neural Transmission</i> , 2022, 129, 239-259.	2.8	8
101	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. <i>Diagnostics</i> , 2022, 12, 796.	2.6	4
102	Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review. <i>European Journal of Neuroscience</i> , 2022, 56, 5650-5713.	2.6	4
103	Blood Biomarkers Predict Future Cognitive Decline after Military-Related Traumatic Brain Injury. <i>Current Alzheimer Research</i> , 2022, 19, 351-363.	1.4	3
104	Novel Ultrasensitive Detection Technologies for the Identification of Early and Minimally Invasive Alzheimer's Disease Blood Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1337-1369.	2.6	4
105	Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels. <i>Communications Biology</i> , 2022, 5, 336.	4.4	6
106	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 199.	6.2	32
108	Bibliometric and Visual Analysis on Metabolomics in Coronary Artery Disease Research. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 804463.	2.4	9
109	Alzheimer's Disease: A Silent Pandemic – A Systematic Review on the Situation and Patent Landscape of the Diagnosis. <i>Recent Patents on Biotechnology</i> , 2022, 16, .	0.8	0
110	Post-Stroke Cognitive Impairment and Dementia. <i>Circulation Research</i> , 2022, 130, 1252-1271.	4.5	188
111	Current trends in blood biomarker detection and imaging for Alzheimer's disease. <i>Biosensors and Bioelectronics</i> , 2022, 210, 114278.	10.1	25

#	ARTICLE	IF	CITATIONS
112	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	10.1	99
113	Plasma p-tau181 associated with structural changes in mild cognitive impairment. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 2139-2147.	2.9	4
114	Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. <i>Brain Communications</i> , 2022, 4, .	3.3	11
115	Tau as a Biomarker of Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7307.	4.1	28
116	The Role of Depressive Symptoms and Physical Activity Levels in Mediating the Association Between HIV Status and Neurocognitive Functions Among Individuals Aged at Least 50 Years in China: Cross-sectional Study. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e32968.	2.6	2
117	Alzheimer's disease: a scoping review of biomarker research and development for effective disease diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 681-703.	3.1	5
118	Associations of sensory and motor function with blood-based biomarkers of neurodegeneration and Alzheimer's disease in midlife. <i>Neurobiology of Aging</i> , 2022, 120, 177-188.	3.1	7
119	Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 119, 1-7.	3.1	5
120	Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 2195-2205.	3.9	10
121	Research Progress of Biomarkers for the Diagnosis of Alzheimer's Disease. <i>Advances in Clinical Medicine</i> , 2022, 12, 7882-7890.	0.0	0
122	Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. <i>Brain</i> , 2022, 145, 4097-4107.	7.6	36
123	Plasma brain injury markers are associated with volume status but not muscle health in heart failure patients. <i>Frontiers in Drug Discovery</i> , 0, 2, .	2.8	1
124	Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases. <i>Fundamental Research</i> , 2023, 3, 505-519.	3.3	4
125	Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges. <i>Revue Neurologique</i> , 2023, 179, 161-172.	1.5	12
126	Graphene as the basis of biological sensors for the diagnosis of neurodegenerative dementia. <i>Izvestiĭ Rossijskoj Voenno-meditsinskoj Akademii</i> , 2022, 41, 421-428.	0.2	1
127	Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample. <i>Neurology</i> , 2023, 100, e874-e883.	1.1	4
128	Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. <i>Brain</i> , 2023, 146, 1152-1165.	7.6	58
129	Machine Learning Reveals a Multipredictor Nomogram for Diagnosing the Alzheimer's Disease Based on Chemiluminescence Immunoassay for Total Tau in Plasma. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	0

#	ARTICLE	IF	CITATIONS
130	Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults. <i>Journal of prevention of Alzheimer's disease</i> , The, 0, , .	2.7	0
131	Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 241-260.	2.6	3
132	The relationship between obstructive sleep apnea and circulating tau levels: A meta-analysis. <i>Brain and Behavior</i> , 2023, 13, .	2.2	5
133	Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia. <i>European Journal of Neurology</i> , 2023, 30, 1565-1573.	3.3	8
134	Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer's disease?. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	3.4	3
135	Plasma Biomarkers of Alzheimer's Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice. <i>Journal of Alzheimer's Disease Reports</i> , 2023, 7, 355-380.	2.2	8
136	Plasma biomarkers for prediction of Alzheimer's disease neuropathologic change. <i>Acta Neuropathologica</i> , 2023, 146, 13-29.	7.7	7
137	Lipidomic markers for the prediction of progression from mild cognitive impairment to Alzheimer's disease. <i>FASEB Journal</i> , 2023, 37, .	0.5	1
138	Targeting gut-brain axis by dietary flavonoids ameliorate aging-related cognition decline: Evidences and mechanisms. <i>Critical Reviews in Food Science and Nutrition</i> , 0, , 1-22.	10.3	1
139	Effectiveness and Safety of Bu Shen Kai Qiao Fang in the Treatment of Alzheimer's Disease: Study Protocol for a Multicenter, Prospective, Real-World Clinical Trial. <i>International Journal of General Medicine</i> , 0, Volume 16, 2573-2583.	1.8	0
140	The association of obstructive sleep apnea with blood and cerebrospinal fluid biomarkers of Alzheimer's dementia - A systematic review and meta-analysis. <i>Sleep Medicine Reviews</i> , 2023, 70, 101790.	8.5	5
141	Associations of Midlife Lifestyle and Health Factors with Long-Term Changes in Blood-Based Biomarkers of Alzheimer's Disease and Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2023, 94, 1381-1395.	2.6	3
142	Tau: a biomarker of Huntington's disease. <i>Molecular Psychiatry</i> , 0, , .	7.9	1
143	Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology. <i>Clinical Chemistry</i> , 0, , .	3.2	0
144	The Major Hypotheses of Alzheimer's Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment. <i>Cells</i> , 2023, 12, 2669.	4.1	1
145	Emerging evidence for dysregulated proteome cargoes of tau-propagating extracellular vesicles driven by familial mutations of tau and presenilin. , 0, 4, 588-98.		0
146	Plasma Amyloid- β 2, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study. <i>Journal of Alzheimer's Disease</i> , 2023, 96, 845-858.	2.6	0
147	Cerebrospinal fluid neurofilament light chain mediates age-associated lower learning and memory in healthy adults. <i>Neurobiology of Aging</i> , 2024, 135, 39-47.	3.1	0

#	ARTICLE	IF	CITATIONS
148	Investigating metabolic dysregulation in serum of triple transgenic Alzheimer’s disease male mice: implications for pathogenesis and potential biomarkers. Amino Acids, 2024, 56, .	2.7	0
149	Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis. Frontiers in Neurology, 0, 15, .	2.4	0